Patent: 7,897,585
✉ Email this page to a colleague
Summary for Patent: 7,897,585
| Title: | Nanoparticles for protein drug delivery |
| Abstract: | The invention discloses the nanoparticles composed of chitosan, poly-glutamic acid, and at least one anti-hemophilic factor or bioactive agent characterized with a positive surface charge and their enhanced permeability in oral drug delivery. |
| Inventor(s): | Sung; Hsing-Wen (Hsinchu, TW), Tu; Hosheng (Newport Beach, CA) |
| Assignee: | GP Medical, Inc. (Newport Beach, CA) National Tsing Hua University (Hsinchu, TW) |
| Application Number: | 12/378,976 |
| Patent Claims: | see list of patent claims |
Details for Patent 7,897,585
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Grifols Therapeutics Llc | KOATE, KOATE-DVI | antihemophilic factor (human) | For Injection | 101130 | January 24, 1974 | ⤷ Start Trial | 2029-02-20 |
| Takeda Pharmaceuticals U.s.a., Inc. | HEMOFIL M | antihemophilic factor (human) | For Injection | 101448 | March 14, 2001 | ⤷ Start Trial | 2029-02-20 |
| Grifols Biologicals Llc | ALPHANATE | antihemophilic factor/von willebrand factor complex (human) | For Injection | 102475 | August 15, 1978 | ⤷ Start Trial | 2029-02-20 |
| Grifols Biologicals Llc | ALPHANATE | antihemophilic factor/von willebrand factor complex (human) | For Injection | 102475 | June 26, 2014 | ⤷ Start Trial | 2029-02-20 |
| Takeda Pharmaceuticals U.s.a., Inc. | BIOCLATE (ARMOUR), RECOMBINATE | antihemophilic factor (recombinant) | For Injection | 103375 | December 10, 1992 | ⤷ Start Trial | 2029-02-20 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
